USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES
Giant-cell tumor is a relatively rare neoplasia, benign but locally aggressive, that causes significant bone destruction with predilection for epiphyseal and metaphyseal regions of long bones and the spine. Definitive treatment is surgical, with complete tumoral resection followed by autograft, homo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia
2019-01-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190009 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846149847837573120 |
|---|---|
| author | Tamise da Silva Baptista Lucilda Cerqueira Lima Aline Rocha Lino Gerson Gandhi Ganev Paulo Kechele Rita Ferrúa Farias de Oliveira |
| author_facet | Tamise da Silva Baptista Lucilda Cerqueira Lima Aline Rocha Lino Gerson Gandhi Ganev Paulo Kechele Rita Ferrúa Farias de Oliveira |
| author_sort | Tamise da Silva Baptista |
| collection | DOAJ |
| description | Giant-cell tumor is a relatively rare neoplasia, benign but locally aggressive, that causes significant bone destruction with predilection for epiphyseal and metaphyseal regions of long bones and the spine. Definitive treatment is surgical, with complete tumoral resection followed by autograft, homograft, arthrodesis, unconventional endoprostheses or methylmethacrylate. In most cases, surgery is accompanied by high morbidity and variable recurrence rates, depending on the site, size and type of surgical intervention.Denosumab, a RANKL inhibitor, acts by decreasing tumoral osteoclastic activity and is approved by the Food and Drug Administration for treatment of GCT when surgery is not possible or when it is associated with high morbidity. This report of cases is based on the review of medical records from the Ambulatory Service for Adolescents and Young Adults (AYA), aiming to show the experience of the Service with the use of denosumab for neoadjuvant purposes. |
| format | Article |
| id | doaj-art-5e53d9f0096d4c9a8558b1465383774b |
| institution | Kabale University |
| issn | 2526-8732 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-5e53d9f0096d4c9a8558b1465383774b2024-11-29T10:30:43ZengSociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de RadioterapiaBrazilian Journal of Oncology2526-87322019-01-011510.5935/2526-8732.20190009USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASESTamise da Silva Baptista0Lucilda Cerqueira Lima1Aline Rocha Lino2Gerson Gandhi Ganev3Paulo Kechele4Rita Ferrúa Farias de Oliveira5CEPON - CENTRO DE PESQUISAS ONCOLÓGICAS. Rod. Admar GonzagaCENTRO DE PESQUISAS ONCOLÓGICAS - CEPON, Ambulatório de Atendimento aos Adolescentes e Jovens Adultos - AJAS - FLORIANÓPOLIS - Santa Catarina - BrazilCENTRO DE PESQUISAS ONCOLÓGICAS - CEPON, Ambulatório de Atendimento aos Adolescentes e Jovens Adultos - AJAS - FLORIANÓPOLIS - Santa Catarina - BrazilCENTRO DE PESQUISAS ONCOLÓGICAS - CEPON, Ambulatório de Atendimento aos Adolescentes e Jovens Adultos - AJAS - FLORIANÓPOLIS - Santa Catarina - BrazilCENTRO DE PESQUISAS ONCOLÓGICAS - CEPON, Ambulatório de Atendimento aos Adolescentes e Jovens Adultos - AJAS - FLORIANÓPOLIS - Santa Catarina - BrazilCENTRO DE PESQUISAS ONCOLÓGICAS - CEPON, Ambulatório de Atendimento aos Adolescentes e Jovens Adultos - AJAS - FLORIANÓPOLIS - Santa Catarina - BrazilGiant-cell tumor is a relatively rare neoplasia, benign but locally aggressive, that causes significant bone destruction with predilection for epiphyseal and metaphyseal regions of long bones and the spine. Definitive treatment is surgical, with complete tumoral resection followed by autograft, homograft, arthrodesis, unconventional endoprostheses or methylmethacrylate. In most cases, surgery is accompanied by high morbidity and variable recurrence rates, depending on the site, size and type of surgical intervention.Denosumab, a RANKL inhibitor, acts by decreasing tumoral osteoclastic activity and is approved by the Food and Drug Administration for treatment of GCT when surgery is not possible or when it is associated with high morbidity. This report of cases is based on the review of medical records from the Ambulatory Service for Adolescents and Young Adults (AYA), aiming to show the experience of the Service with the use of denosumab for neoadjuvant purposes.http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190009DenosumabRANK LigandGiant Cell Tumors.DenosumabLigando RANKTumores de Células Gigantes. |
| spellingShingle | Tamise da Silva Baptista Lucilda Cerqueira Lima Aline Rocha Lino Gerson Gandhi Ganev Paulo Kechele Rita Ferrúa Farias de Oliveira USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES Brazilian Journal of Oncology Denosumab RANK Ligand Giant Cell Tumors. Denosumab Ligando RANK Tumores de Células Gigantes. |
| title | USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES |
| title_full | USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES |
| title_fullStr | USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES |
| title_full_unstemmed | USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES |
| title_short | USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES |
| title_sort | use of denosumab in giant cell tumor at a public hospital in southern brazil report of 13 cases |
| topic | Denosumab RANK Ligand Giant Cell Tumors. Denosumab Ligando RANK Tumores de Células Gigantes. |
| url | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190009 |
| work_keys_str_mv | AT tamisedasilvabaptista useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases AT lucildacerqueiralima useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases AT alinerochalino useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases AT gersongandhiganev useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases AT paulokechele useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases AT ritaferruafariasdeoliveira useofdenosumabingiantcelltumoratapublichospitalinsouthernbrazilreportof13cases |